- The FDA has greenlit Roche Holdings AG's RHHBY Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with the expression of the PD-L1 biomarker covering at least 1% of tumor cells.
- Related: After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US.
- The agency based its review on data from the Phase 3 IMpower010 study, which showed adjuvant Tecentriq cut the risk of relapse or death by 34% over best supportive care.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: RHHBY shares are up 0.45% at $49.14 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
